The life science industry has long faced the lengthy and costly process of developing new drugs and medical devices: it takes about 2.6$ bn and up to 12 years to bring new medicines to the market. Digital Twin and Biosimulation are the key to cutting down time frames and costs, and regulatory tailwinds are pushing heavily in this direction. The pandemic-induced disruption in Pharma and R&D has also paved the way for a new trial paradigm.
At InSilicoTrials, we have extensive experience with regulatory agencies around the globe, such as EMA and the FDA.
We can support your regulatory processes and ensure the documentation needed on your pathway towards compliance is scientifically focused and practical.
[formidable id=”14″]